Conatus Pharmaceuticals Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (23)

Latest Posts

About This Stock More About This Stock
Conatus Soars On Novartis Deal, Early FDA Nod For Clovis Drug
Article By: Arpita Dutt
Wednesday, December 21, 2016 10:55 AM EST
Conatus is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. Investors applauded the deal sending the company’s shares soaring 141.3%.
In this article: ALIOF, ALXN, BIIB, CLVS, GILD, CNAT, TSRO
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Article By: Arpita Dutt
Thursday, September 22, 2016 1:45 PM EST
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
In this article: ICPT, CNAT, GALT, ENTA, GLMD Also: AGN
Read
E Shares Of Conatus Up 22% On FDA Fast Track Designation For NASH Cirrhosis
Article By: Terry Chrisomalis
Thursday, February 4, 2016 2:38 AM EST
Yesterday, shares of Conatus Pharmaceuticals closed the day up 22% after the company announced that the FDA had granted the company's drug, Emricasan, FDA fast track status for NASH Cirrhosis.
In this article: CNAT
Read
Morning Call - January 6, 2016
Article By: Jim Van Meerten
Wednesday, January 6, 2016 4:26 PM EST
Apple fell nearly 3% in pe-market trading after the Nikkei Asian Review reported that Apple would reduce Q1 output of its latest iPhones by about 30%.
In this article: AN, FCX, MON, MSM, PXD, RPM, ACAD, NUVA, AAPL, COST, GILD, LNDC, ORCL, SIRI, SONC, EPZM, CNAT
Read
Regulus And AstraZeneca To Advance Big Potential NASH Drug
Article By: Terry Chrisomalis
Tuesday, April 7, 2015 7:24 PM EST
AstraZeneca okays go-ahead for microRNA therapeutics in additional area.
In this article: RGLS, AZN, ICPT, CNAT, LJPC
Read

PARTNER HEADLINES

Latest Tweets for $CNAT

No tweets yet!